Search

Displaying results 651 - 660 of 841 in total
  1. Drug

    Berdazimer

    go.drugbank.com/drugs/DB18712
    Approved

    It is one of the 5 most prevalent skin diseases in the world and the third-most common viral skin infection in children.

  2. Drug

    VB10.16

    go.drugbank.com/drugs/DB17512
    Investigational

    It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting

  3. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis.

  4. Drug

    1alpha,24S-Dihydroxyvitamin D2

    go.drugbank.com/drugs/DB06117
    Experimental

    LR-103 is one of the D-hormones produced from Hectorol. It is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD).

  5. Drug

    BNT162a1 SARS-CoV-2 Vaccine

    go.drugbank.com/drugs/DB15697
    Experimental

    BNT162a1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.

  6. Drug

    BNT162c2 SARS-CoV-2 Vaccine

    go.drugbank.com/drugs/DB15698
    Experimental

    BNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.

  7. Drug

    NAV 1800

    go.drugbank.com/drugs/DB05437
    Experimental

    RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal cancer.

  8. Drug

    Aplaviroc

    go.drugbank.com/drugs/DB06497
    Investigational

    A spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.

  9. Drug

    Vardenafil

    go.drugbank.com/drugs/DB00862
    Approved

    Compared to [sildenafil] and [tadalafil], vardenafil is a more potent inhibitor of PDE5; however, its selectivity for other PDE isoforms is lower than the one detected for tadalafil.

  10. Drug

    Angiotensin II

    go.drugbank.com/drugs/DB11842
    ApprovedInvestigational

    As distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment